AU2003209924A1 - Compounds and methods of treating cell proliferative diseases - Google Patents

Compounds and methods of treating cell proliferative diseases Download PDF

Info

Publication number
AU2003209924A1
AU2003209924A1 AU2003209924A AU2003209924A AU2003209924A1 AU 2003209924 A1 AU2003209924 A1 AU 2003209924A1 AU 2003209924 A AU2003209924 A AU 2003209924A AU 2003209924 A AU2003209924 A AU 2003209924A AU 2003209924 A1 AU2003209924 A1 AU 2003209924A1
Authority
AU
Australia
Prior art keywords
pyran
eht
yield
nmr
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003209924A
Other languages
English (en)
Inventor
Eric Beausoleil
Veronique Leblanc
Bertrand Leblond
Maria Luz Lopez Rodriguez
Dominique Melle-Milovanovic
Virginie Picard
Maria Del Carmen Pinar Pinedo
Thierry Traverne
Alma Viso Beronda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ExonHit Therapeutics SA
Original Assignee
ExonHit Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ExonHit Therapeutics SA filed Critical ExonHit Therapeutics SA
Publication of AU2003209924A1 publication Critical patent/AU2003209924A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2003209924A 2002-03-01 2003-02-28 Compounds and methods of treating cell proliferative diseases Abandoned AU2003209924A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/085,141 2002-03-01
US10/085,141 US6552073B1 (en) 2002-03-01 2002-03-01 Compounds and methods of treating cell proliferative diseases
PCT/IB2003/001050 WO2003074508A1 (en) 2002-03-01 2003-02-28 Compounds and methods of treating cell proliferative diseases

Publications (1)

Publication Number Publication Date
AU2003209924A1 true AU2003209924A1 (en) 2003-09-16

Family

ID=22189708

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003209924A Abandoned AU2003209924A1 (en) 2002-03-01 2003-02-28 Compounds and methods of treating cell proliferative diseases

Country Status (6)

Country Link
US (2) US6552073B1 (enExample)
EP (1) EP1480966A1 (enExample)
JP (1) JP2005529079A (enExample)
AU (1) AU2003209924A1 (enExample)
CA (1) CA2477003A1 (enExample)
WO (1) WO2003074508A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552073B1 (en) * 2002-03-01 2003-04-22 Exonhit Therapeutics Sa Compounds and methods of treating cell proliferative diseases
EP1471063A1 (en) * 2003-02-28 2004-10-27 Exonhit Therapeutics S.A. Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis
WO2005110399A2 (en) * 2004-04-29 2005-11-24 The Regents Of The University Of California Zinc-binding groups for metalloprotein inhibitors
EP1755586A2 (en) * 2004-04-29 2007-02-28 The Regents of the University of California Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
WO2018037295A1 (en) * 2016-08-23 2018-03-01 Neurim Pharmaceuticals (1991) Ltd. Method for treating pruritus and/or itch

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812584A (en) * 1984-07-11 1989-03-14 G. D. Searle & Co. Aralkoxy and aryloxyalkoxy kojic acid derivatives
US4644071A (en) * 1984-07-11 1987-02-17 G. D. Searle & Co. Aralkoxy and aryloxyalkoxy kojic acid derivatives
US4705871A (en) * 1984-07-11 1987-11-10 G. D. Searle & Co. Aralkoxy and aryloxyalkoxy kojic acid derivatives
PH22520A (en) * 1984-11-12 1988-10-17 Yamanouchi Pharma Co Ltd Heterocyclic compounds having 4-lover alkyl-3-hydroxy-2-lower alkyl phenoxy-lower alkylene-y-group, and process of producing them
US6552073B1 (en) * 2002-03-01 2003-04-22 Exonhit Therapeutics Sa Compounds and methods of treating cell proliferative diseases

Also Published As

Publication number Publication date
US6552073B1 (en) 2003-04-22
JP2005529079A (ja) 2005-09-29
EP1480966A1 (en) 2004-12-01
WO2003074508A1 (en) 2003-09-12
US20050054629A1 (en) 2005-03-10
WO2003074508B1 (en) 2003-11-27
CA2477003A1 (en) 2003-09-12

Similar Documents

Publication Publication Date Title
KR102720992B1 (ko) 피롤리딘 화합물
US8008496B2 (en) 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents
US6608052B2 (en) Compounds useful as anti-inflammatory agents
US8530490B2 (en) Uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity
US20090156601A1 (en) Pyrimidine derivatives for the treatment of cancer
US8642643B2 (en) CXCR2 antagonists
US20060089371A1 (en) Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
BG65159B1 (bg) Хетероциклични производни на уреа, полезни като противовъзпалителни средства
EP1471063A1 (en) Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis
WO2002096876A1 (en) Carbamate and oxamide compounds as inhibitors of cytokine production
US20100298402A1 (en) Stilbene derivatives as pstat3/il-6 inhibitors
US20070111998A1 (en) Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors
JPH11269140A (ja) 分化誘導剤
US10357477B2 (en) Anticancer compounds
AU2003209924A1 (en) Compounds and methods of treating cell proliferative diseases
AU2005254945C1 (en) 2,4-Diaminoquinazolines for spinal muscular atrophy
JP3078333B2 (ja) 抗ウイルス性２，４―ピリミジンジオン誘導体およびその製造方法
KR20070121028A (ko) 치환된 아미노알킬- 및 아미도알킬-벤조피란 유도체
US10059663B2 (en) Aromatic compound and use thereof
KR20250023339A (ko) 페닐 트라이아졸 mll1-wdr5 단백질-단백질 상호작용 저해제
US8067459B2 (en) Lapachone compounds and methods of use thereof
JP5330377B2 (ja) ３，４−ジヒドロキナゾリン誘導体
JP3492433B2 (ja) ３−（フェニルアルキルアミノアルキルオキシ）−５−フェニルピラゾール−化合物、その製造のための方法及び中間体、及びこれを含有する心臓循環作用薬剤
US8053459B1 (en) Selenolopyrazole derivatives and use thereof as anticancer agents
JPH0570453A (ja) アミノメチルイソクロマン誘導体およびその製造方法

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period